Aam Slc Low Duration Income ETF (LODI) Trades

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care. The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events. Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales. While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX. Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk. Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success. Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan. #proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk #LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason

Southern Cross Gold Consolidated CEO Michael Hudson talked with Proactive at the AIM's Small and Midcap Conference about the company’s focus on gold and antimony exploration in Victoria, Australia, particularly at the Sundae Creek project. Hudson outlined the scale and significance of the discovery, describing it as “one of the most exciting gold discoveries globally… a rare tier one multi-million ounce high grade discovery.” The company is advancing exploration rapidly, with six drill rigs currently operating and plans to expand to eight. Hudson said the company has completed around 70km of drilling and estimates an exploration target of 2.2 to 3.2 million ounces gold equivalent, grading between 8.5 to 10.6 grams per tonne – all within just 5% of the identified trend. Antimony also plays a key role. Hudson explained that China and Russia dominate the global market and recent export bans have highlighted supply vulnerabilities: “You don't have a defense industry without it. And the Western world really doesn't have it. We've got it.” Hudson also reflected on the company’s recent inclusion in the All Ordinaries Index, following the merger of Canadian and Australian entities. He said it marks the first index entry for Southern Cross Gold Consolidated and is “a reflection on a business that's less than three years old.” #SouthernCrossGold #SundayCreek #GoldExploration #Antimony #ASX #MiningStocks #JuniorMiners #ResourceInvesting #MichaelHudson #AllOrdinaries #GoldAndAntimony #AustralianMining

Digitalbox PLC (AIM:DBOX) CEO James Carter takes Proactive's Stephen Gunnion through the company’s strong 2024 performance and its strategy heading into 2025. The company delivered a 31% increase in revenue during the year, with Carter describing it as “a good turnaround year.” He pointed to audience growth that outperformed broader news media trends, and revenue growth that exceeded global digital advertising market averages. Carter credited the success to the strength of Digitalbox’s brands and editorial teams, as well as the company’s in-house Graphene Ad Stack technology. “The editorial teams are really very well tuned into what their audiences want,” he said. Among standout performers were TV Guide, which achieved 90% traffic growth in Q4 following a move to a web app format, and The Tab, which benefited from social media asset integration. The Poke also saw a 22% increase in traffic following increased content investment. The company expanded its portfolio from six to eight brands in 2024, aiming to reach ten by the end of 2025. Looking ahead, Carter said 2025 is in line with expectations so far, and Digitalbox remains “cautiously optimistic” amid projected 10% growth in the digital ad market. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #Digitalbox #JamesCarter #MediaGrowth #DigitalAdvertising #TVGuide #TheTab #OnlineMedia #RevenueGrowth #AdTech #MediaBrands #InvestorUpdate #ProactiveInvestors